MA41866A - Molécules à auto-assemblage pour l'administration ciblée de médicaments - Google Patents
Molécules à auto-assemblage pour l'administration ciblée de médicamentsInfo
- Publication number
- MA41866A MA41866A MA041866A MA41866A MA41866A MA 41866 A MA41866 A MA 41866A MA 041866 A MA041866 A MA 041866A MA 41866 A MA41866 A MA 41866A MA 41866 A MA41866 A MA 41866A
- Authority
- MA
- Morocco
- Prior art keywords
- self
- drug delivery
- targeted drug
- assembling molecules
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/189—Host-guest complexes, e.g. cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562140696P | 2015-03-31 | 2015-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41866A true MA41866A (fr) | 2018-02-06 |
Family
ID=57007332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041866A MA41866A (fr) | 2015-03-31 | 2016-03-30 | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180140719A1 (fr) |
EP (2) | EP3277268A4 (fr) |
JP (2) | JP2018513142A (fr) |
CN (1) | CN107613963A (fr) |
AU (1) | AU2016242920B2 (fr) |
CA (1) | CA2980329C (fr) |
HK (1) | HK1248540A1 (fr) |
MA (1) | MA41866A (fr) |
MX (2) | MX2017012187A (fr) |
WO (1) | WO2016161129A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41866A (fr) * | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
WO2019079767A1 (fr) * | 2017-10-20 | 2019-04-25 | The General Hospital Corporation | Agents immunothérapeutiques ciblant les macrophages |
US20230065416A1 (en) * | 2020-01-28 | 2023-03-02 | Nanotomer, Inc. | Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo |
WO2021160873A1 (fr) * | 2020-02-13 | 2021-08-19 | Eth Zurich | Nanoparticules encapsulant de petites molécules |
CN112229887B (zh) * | 2020-09-02 | 2022-07-22 | 中国科学院深圳先进技术研究院 | 一种可精准编辑酶/电极界面及其制备方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
ES2274572T3 (es) | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek. |
PT993439E (pt) | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
CA2349832A1 (fr) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek |
AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 4′ヘテロアリールジアリールアミン |
PL348870A1 (en) | 1999-01-13 | 2002-06-17 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
ES2247859T3 (es) | 1999-01-13 | 2006-03-01 | Warner-Lambert Company Llc | Benzoheterociclos y su uso como inhibidores de mek. |
CA2348236A1 (fr) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek |
GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
ES2269458T3 (es) | 2000-09-15 | 2007-04-01 | Vertex Pharmaceuticals Incorporated | Isoxazoles y su uso como inhibidores de la erk. |
US20030049203A1 (en) * | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
PT3000810T (pt) | 2002-03-13 | 2017-10-25 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7772234B2 (en) | 2003-11-19 | 2010-08-10 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
DK2161336T4 (en) * | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
DK1922307T3 (da) | 2005-05-18 | 2012-04-02 | Array Biopharma Inc | Heterocykliske inhibitorer af MEK og fremgangsmåder til anvendelse heraf |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
WO2007025090A2 (fr) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibiteurs de kinase mapk/erk |
DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
EP2069308B1 (fr) | 2006-09-12 | 2017-03-29 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Composés dérivés d'azonafide pour le ciblage de tumeurs et de cancers |
CN101663279A (zh) | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
US20090035389A1 (en) * | 2007-02-23 | 2009-02-05 | Specigen Inc. | Targeted protein cages |
MX2010006800A (es) | 2007-12-19 | 2010-10-05 | Genentech Inc | 5-anilinoimidazopiridinas y metodos de uso de las mismas. |
US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
CA2779843A1 (fr) | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie d'un cancer |
WO2014141289A1 (fr) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Composition pour photochimiothérapie à base de microcapsules à structure cœur-écorce |
WO2015108783A1 (fr) | 2014-01-16 | 2015-07-23 | The Brigham And Women's Hospital, Inc. | Administration ciblée de médicaments immunorégulateurs |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
-
2016
- 2016-03-30 MA MA041866A patent/MA41866A/fr unknown
- 2016-03-31 CA CA2980329A patent/CA2980329C/fr active Active
- 2016-03-31 EP EP16774208.9A patent/EP3277268A4/fr not_active Withdrawn
- 2016-03-31 AU AU2016242920A patent/AU2016242920B2/en active Active
- 2016-03-31 CN CN201680030763.8A patent/CN107613963A/zh active Pending
- 2016-03-31 US US15/563,339 patent/US20180140719A1/en not_active Abandoned
- 2016-03-31 EP EP21178644.7A patent/EP3936121A1/fr active Pending
- 2016-03-31 JP JP2017551201A patent/JP2018513142A/ja active Pending
- 2016-03-31 WO PCT/US2016/025290 patent/WO2016161129A1/fr active Application Filing
- 2016-03-31 MX MX2017012187A patent/MX2017012187A/es unknown
-
2017
- 2017-09-25 MX MX2022009027A patent/MX2022009027A/es unknown
-
2018
- 2018-06-26 HK HK18108192.9A patent/HK1248540A1/zh unknown
-
2019
- 2019-11-25 US US16/694,437 patent/US11666664B2/en active Active
-
2021
- 2021-04-01 JP JP2021062630A patent/JP2021113196A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016161129A1 (fr) | 2016-10-06 |
EP3936121A1 (fr) | 2022-01-12 |
CN107613963A (zh) | 2018-01-19 |
EP3277268A1 (fr) | 2018-02-07 |
AU2016242920B2 (en) | 2021-10-21 |
CA2980329C (fr) | 2024-01-23 |
US11666664B2 (en) | 2023-06-06 |
US20180140719A1 (en) | 2018-05-24 |
JP2018513142A (ja) | 2018-05-24 |
EP3277268A4 (fr) | 2018-12-05 |
MX2022009027A (es) | 2022-08-11 |
HK1248540A1 (zh) | 2018-10-19 |
JP2021113196A (ja) | 2021-08-05 |
AU2016242920A1 (en) | 2017-10-12 |
MX2017012187A (es) | 2018-01-09 |
CA2980329A1 (fr) | 2016-10-06 |
US20200078472A1 (en) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50557A (fr) | Pistons pour dispositifs d'administration de médicament | |
MA51617A (fr) | Mécanisme d'administration de médicament | |
DK3368108T3 (da) | Medikamenttilførselsanordning | |
MA41265A (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
DK3886944T3 (da) | Lægemiddelafgivelsesindretning | |
MA48050A (fr) | Lipides biodégradables pour l'administration d'acides nucléiques | |
MA43574A (fr) | Compositions ayant des amplificateurs de perméation pour l'administration de médicaments | |
MA41866A (fr) | Molécules à auto-assemblage pour l'administration ciblée de médicaments | |
DK3357491T3 (da) | Farmaceutisk sammensætning til afgivelse af et anionisk medikament | |
MA45472A (fr) | Systèmes d'administration pour la libération contrôlée de médicaments | |
HK1255638A1 (zh) | 用於延長給藥的液體聚合物遞送系統 | |
DK3380139T3 (da) | Medikamentadministrationsanordning | |
HK1252771A1 (zh) | 用於治療眼部病狀的玻璃體內藥物遞送系統 | |
DK3380146T3 (da) | Medikamentadministrationsanordning | |
ITUB20152886A1 (it) | Dispositivo di sicurezza per l'irrigazione nasale | |
IL271859A (en) | Continuous production of drug molecule conjugates for guidance | |
EP3532131A4 (fr) | Dispositif portable d'administration de médicament | |
MA42458A (fr) | Systèmes améliorés d'administration de nanoparticules | |
KR101743399B9 (ko) | 폴리에틸렌글리콜과 트리페닐포스포늄이 컨쥬게이트된 물질 및 이를 적용한 미토콘드리아 표적 자기조립형 나노약물 전달체 | |
DK3558423T3 (da) | Medikamentadministrationsanordning | |
DK3570911T3 (da) | Medikamenttilførselsanordning | |
DK3449892T3 (da) | Lægemiddeludleveringsapparat | |
DK3453390T3 (da) | Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel | |
DK3349825T3 (da) | Lægemiddeladministrationsanordning | |
IT201700043316A1 (it) | Drug delivery system |